Treatment considerations of cervical spondylotic myelopathy
- PMID: 29473581
- PMCID: PMC5764527
- DOI: 10.1212/CPJ.0000000000000050
Treatment considerations of cervical spondylotic myelopathy
Abstract
Cervical spondylotic myelopathy (CSM) is the leading cause of myelopathy in patients over age 50 years. Despite advances, CSM remains a clinical diagnosis and its natural history remains unclear. The treatment of CSM is controversial, especially in patients with mild or moderate clinical disease without rapid progression of symptoms. Herein, we begin with a clinical vignette followed by a brief description of the clinical problems. We discuss evaluation, treatment, and recommendations for the treatment of CSM. Emphasis is drawn to areas of uncertainty and present level of evidence for the treatment modalities of CSM.
Figures

References
-
- Kalsi-Ryan S, Karadismas SK, Fehlings MG. Cervical spondylotic myelopathy: the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder. Neuroscientist. 2013;19:409–421. - PubMed
-
- Wilkinson M. The morbid anatomy of cervical spondylotic and myelopathy. Brain. 1960;83:589–616. - PubMed
-
- Young WF. Cervical spondylotic myelopathy: a common cause of spinal cord dysfunction in older persons. Am Fam Physician. 2000;62:1064–1070. - PubMed
-
- Clark E, Robinson PK. Cervical myelopathy: complication of cervical spondylosis. Brain. 1956;79:483–510. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources